Search the collection

Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 21
Newsletter articlesFull Text
Sage Therapeutics' SAGE-718 granted orphan drug designationfor Huntington’s disease
Publisher:London: Normans Media Ltd
Journal title:M2 Pharma, 2023
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 22
Newsletter articlesFull Text
Sage Therapeutics Shares Rise 12% After Positive Data for SAGE-718
Publisher:New York: Dow Jones & Company Inc
Journal title:Dow Jones Institutional News, 2022
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 23
ReportsFull Text
Parkinson Agent Solengepras Enters Phase 3, Sage to Discontinue SAGE-718, Serious Adverse Event Reported in Gene Therapy Study of NGN-401
Publisher:Intellisphere, LLC
Journal title:Neurology Live, 2024
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 24
Newsletter articlesFull Text
Sage Therapeutics: U.S. FDA Grants SAGE-718 Orphan Drug Designation for the Treatment of Huntington's Disease
Publisher:Jacksonville: Close-Up Media, Inc
Journal title:Wireless News, 2023
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 25
Newsletter articlesFull Text
Sage Therapeutics: U.S. FDA Grants SAGE-718 Orphan Drug Designation for the Treatment of Huntington's Disease
Publisher:Jacksonville: Close-Up Media, Inc
Journal title:Professional Services Close - Up, 2023
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 26
Newsletter articlesFull Text
Sage Therapeutics: U.S. FDA Grants SAGE-718 Orphan Drug Designation for the Treatment of Huntington's Disease
Publisher:Jacksonville: Close-Up Media, Inc
Journal title:Health & Beauty Close - Up, 2023
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 27
Newsletter articlesFull Text
Sage Therapeutics to Host Sage Science Spotlight: SAGE-718 In Depth
Publisher:New York: Business Wire
Journal title:Business Wire, 2021
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 28
Newsletter articlesFull Text
European Medicines Grants SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
Publisher:London: Normans Media Ltd
Journal title:M2 Pharma, 2023
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 29
Newsletter articlesFull Text
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease
Publisher:Melbourne: News Bites Pty Ltd
Journal title:News Bites US - NASDAQ, 2024
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 30
Newsletter articlesFull Text
Press Release: Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease
Publisher:New York: Dow Jones & Company Inc
Journal title:Dow Jones Institutional News, 2024
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 31
Newsletter articlesFull Text
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
Publisher:New York: Business Wire
Journal title:Business Wire, 2024
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 32
ReportsFull Text
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor SAGE-718 in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer's Disease
Publisher:NewsRX LLC
Journal title:Mental Health Weekly Digest, 2024, p.51
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 33
ReportsFull Text
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor SAGE-718 in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer's Disease
Publisher:NewsRX LLC
Journal title:Mental Health Weekly Digest, 2024, p.51
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 34
Newsletter articlesFull Text
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor SAGE-718 in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer's Disease
Publisher:NewsRX LLC
Journal title:Mental Health Weekly Digest, 2024, p.51
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 35
Newsletter articlesFull Text
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer's Disease
Publisher:Melbourne: News Bites Pty Ltd
Journal title:News Bites US - NASDAQ, 2024
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 36
Newsletter articlesFull Text
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
Publisher:New York: Business Wire
Journal title:Business Wire, 2024
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 37
Newsletter articlesFull Text
Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
Publisher:New York: Business Wire
Journal title:Business Wire, 2023
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 38
ReportsFull Text
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor SAGE-718 in the Treatment of Mild Cognitive Impairment in Parkinson's Disease
Publisher:NewsRX LLC
Journal title:Obesity, Fitness & Wellness Week, 2024, p.37
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 39
ReportsFull Text
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor SAGE-718 in the Treatment of Mild Cognitive Impairment in Parkinson's Disease
Publisher:NewsRX LLC
Journal title:Obesity, Fitness & Wellness Week, 2024, p.37
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 40
Newsletter articlesFull Text
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Publisher:New York: Business Wire
Journal title:Business Wire, 2024
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.

Showing 21 to 40 of 86 results

Search the collection

Export record to excel

Export this record

Export record to excel

Sage Therapeutics' SAGE-718 granted orphan drug designationfor Huntington’s disease

Export this record

Export record to excel

Sage Therapeutics Shares Rise 12% After Positive Data for SAGE-718

Export this record

Export record to excel

Parkinson Agent Solengepras Enters Phase 3, Sage to Discontinue SAGE-718, Serious Adverse Event Reported in Gene Therapy Study of NGN-401

Export this record

Export record to excel

Sage Therapeutics: U.S. FDA Grants SAGE-718 Orphan Drug Designation for the Treatment of Huntington's Disease

Export this record

Export record to excel

Sage Therapeutics: U.S. FDA Grants SAGE-718 Orphan Drug Designation for the Treatment of Huntington's Disease

Export this record

Export record to excel

Sage Therapeutics: U.S. FDA Grants SAGE-718 Orphan Drug Designation for the Treatment of Huntington's Disease

Export this record

Export record to excel

Sage Therapeutics to Host Sage Science Spotlight: SAGE-718 In Depth

Export this record

Export record to excel

European Medicines Grants SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease

Export this record

Export record to excel

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease

Export this record

Export record to excel

Press Release: Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease

Export this record

Export record to excel

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease

Export this record

Export record to excel

Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor SAGE-718 in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer's Disease

Export this record

Export record to excel

Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor SAGE-718 in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer's Disease

Export this record

Export record to excel

Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor SAGE-718 in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer's Disease

Export this record

Export record to excel

Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer's Disease

Export this record

Export record to excel

Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease

Export this record

Export record to excel

Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease

Export this record

Export record to excel

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor SAGE-718 in the Treatment of Mild Cognitive Impairment in Parkinson's Disease

Export this record

Export record to excel

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor SAGE-718 in the Treatment of Mild Cognitive Impairment in Parkinson's Disease

Export this record

Export record to excel

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease

Refine your search